Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

705
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
705
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

443
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
443
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

506
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
506
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

477
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
477
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

437
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
437
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Recovery After Surgery for patients undergoing radical cystectomy: Surgeons' perspectives and recommendations ten years after its implementation.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.

Diabetes, obesity & metabolism·2025
Same author

Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.

Urologic oncology·2024
Same author

Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approach.

Minerva urology and nephrology·2024
Same author

Human subjects with impaired beta-cell function and glucose tolerance have higher levels of intra-islet intact GLP-1.

Metabolism: clinical and experimental·2024
Same author

Postprandial hypoglycaemia after gastric bypass in type 2 diabetes: pathophysiological mechanisms and clinical implications.

Diabetologia·2024

Related Experiment Video

Updated: Dec 13, 2025

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets
08:50

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets

Published on: July 3, 2018

15.2K

Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.

Ali Muhammed Ali1, Andrea Mari1, Robert Martinez1

  • 1Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas.

The Journal of Clinical Endocrinology and Metabolism
|August 4, 2020
PubMed
Summary
This summary is machine-generated.

Combination therapy with canagliflozin and liraglutide improved beta cell glucose sensitivity in type 2 diabetes patients. This enhanced sensitivity was the primary driver for reduced HbA1c levels, with no additive benefit from the combination over liraglutide alone.

Keywords:
beta cell functioncanagliflozininsulin secretionliraglutide

More Related Videos

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.5K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.6K

Related Experiment Videos

Last Updated: Dec 13, 2025

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets
08:50

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets

Published on: July 3, 2018

15.2K
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.5K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.6K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by impaired insulin secretion and action.
  • Beta cell dysfunction is a key feature of T2DM pathogenesis, leading to inadequate insulin production.
  • Combination therapies are increasingly explored to improve glycemic control and beta cell function in T2DM.

Purpose of the Study:

  • To evaluate the impact of combination therapy with canagliflozin and liraglutide on beta cell function in T2DM patients.
  • To compare the effects of canagliflozin plus liraglutide versus each agent alone on glycemic control and beta cell function.

Main Methods:

  • A randomized controlled trial involving 45 T2DM patients with poor glycemic control (HbA1c 7%-11%).
  • Patients received 16 weeks of treatment with liraglutide (LIRA), canagliflozin (CANA), or a combination (CANA/LIRA).
  • Oral glucose tolerance tests (OGTT) were performed before and after treatment to assess insulin secretion and beta cell glucose sensitivity.

Main Results:

  • Both LIRA and CANA monotherapy, as well as the combination, significantly reduced HbA1c levels.
  • Insulin secretion and beta cell glucose sensitivity increased significantly in all treatment groups.
  • The increase in beta cell glucose sensitivity was strongly and inversely correlated with HbA1c reduction, and was the strongest predictor of HbA1c decrease.

Conclusions:

  • Improved beta cell glucose sensitivity is the primary mechanism underlying HbA1c reduction with canagliflozin and liraglutide in T2DM.
  • Canagliflozin did not provide an additive benefit in improving beta cell glucose sensitivity beyond that achieved with liraglutide monotherapy.